U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 3C6H5O7.4Fe.3O7P2.9H
Molecular Weight 1321.581
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FERRIC PYROPHOSPHATE CITRATE

SMILES

[H+].[H+].[H+].[H+].[H+].[H+].[H+].[H+].[H+].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O

InChI

InChIKey=SXAWSYZURCZSDX-UHFFFAOYSA-B
InChI=1S/3C6H8O7.4Fe.3H4O7P2/c3*7-3(8)1-6(13,5(11)12)2-4(9)10;;;;;3*1-8(2,3)7-9(4,5)6/h3*13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;;;3*(H2,1,2,3)(H2,4,5,6)/q;;;4*+3;;;/p-12

HIDE SMILES / InChI
Molecular Formula Fe
Molecular Weight 55.845
Charge 3
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula O7P2
Molecular Weight 173.9433
Charge -4
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C6H5O7
Molecular Weight 189.0997
Charge -3
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula H
Molecular Weight 1.0079
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Sources: http://www.mfc.co.jp/english/eng/product/sanferol/pdf/fls_gras_notice.pdfhttps://mistralhowto.wordpress.com/2012/03/12/what-is-pigment-yellow-42-and-what-is-it-used-for/ | http://sensientfoodcolors.com/en-us/confection/iron-oxides-approved-by-the-fda/ | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?fr=73.2250 | https://www.drugs.com/inactive/ferric-oxide-yellow-381.htmlhttps://books.google.ru/books?id=vxtxWneRBN4C&pg=PA1103&#v=onepage&q&f=falsehttps://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205874Orig1s000PharmR.pdfhttp://www.edta-chelate.com/ferric-ammonium-edta-liquid--1640836.htmlhttps://books.google.ru/books?id=3hLmyma2-MsC&pg=PA241&lpg=PA241&dq=FERRIC+AMMONIUM+CHLORIDE retrieved from A Consumer's Dictionary of Cosmetic Ingredients, 7th Edition: Complete Information About the Harmful and Desirable Ingredients Found in Cosmetics and Cosmeceuticals By Ruth Winterhttps://www.ncbi.nlm.nih.gov/pubmed/27995746 | http://onlinelibrary.wiley.com/doi/10.1002/047084289X.rn01568/abstract?userIsAuthenticated=false&deniedAccessCustomisedMessage=https://cameochemicals.noaa.gov/chemical/3468 | https://www.ncbi.nlm.nih.gov/pubmed/2135524https://www.ncbi.nlm.nih.gov/pubmed/27684194 | https://www.ncbi.nlm.nih.gov/pubmed/17511797 | https://www.ncbi.nlm.nih.gov/pubmed/1427505
Curator's Comment: description was created based on several sources, including https://www.gpo.gov/fdsys/pkg/CFR-1996-title21-vol3/pdf/CFR-1996-title21-vol3-sec182-5375.pdf

Ferric chloride is a compound used as a food additive, a haemostatic or treatment for hypochromic anaemia. Ferric chloride induced vascular injury is a widely used model of occlusive thrombosis that reports platelet activation and aggregation in the context of an aseptic closed vascular system. Iron i.v. ferric chloride (960 mg) has being shown to be effective in correcting anaemia in HD patients with iron deficiency.

Originator

Monsanto Chemicals
44
Curator's Comment: The relation between phosphate level and ferric citrate consumption was first discovered in 1940s.

Approval Year

1921
1467
Targets

Targets

Primary TargetPharmacologyConditionPotency
Activator
1430
Chelating Agent
142
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
Additrace N

Approved Use

A source of electrolytes and trace elements as an integral part of a complete intravenous nutritional regimen, for adults and children over 40 kg.
Preventing
Approved
8429
Parmirin

Approved Use

Preventive treatment of iron deficiency
Primary
Basic research
Unknown

Approved Use

Unknown
Primary
Approved
8429
SANFEROL

Approved Use

It has also been reported that SFC preparation improved iron deficiency in a pregnant woman with iron deficiency anemia whose hemoglobin level had not increased after administration of other iron preparations such as ferrous fumarate. A dairy supplemental dose of SFC improved iron deficiency in young women with iron deficiency.
Inactive ingredient
Approved
8429
Oxycontin

Approved Use

OxyContin is used in the treatment of chronic pain; pain and belongs to the drug class narcotic analgesics.

Launch Date

9.0935997E11
Curative
Approved
8429
RADIOGARDASE

Approved Use

Insoluble Prussian blue is indicated for treatment of patients with known or suspected internal contamination with radioactive cesium and/or radioactive or non-radioactive thallium to increase their rates of elimination.

Launch Date

1.06496642E12
Palliative
Approved
8429
AURYXIA

Approved Use

Ferric Citrate is a phosphate binder indicated for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis.

Launch Date

1.40978881E12
PubMed

PubMed

TitleDatePubMed
[Effects of ferric fluoride compounds on dental enamel].
1954 Nov 15
The formation of ferritin from apoferritin. Kinetics and mechanism of iron uptake.
1972 Jan
The formation of ferritin from apoferritin. Catalytic action of apoferritin.
1973 Oct
The absorption of iron as supplements in infant cereal and infant formulas.
1975 May
Biological availability of iron supplements for rats, chicks and humans.
1976 Feb
Contact dermatitis to yellow iron oxide.
1985 Aug
Carcinogenicity studies on natural and man-made fibres with the intraperitoneal test in rats.
1989
Effect of physical exercise and vitamin C on absorption of ferric sodium citrate.
1996 Dec
New phosphate binding agents: ferric compounds.
1999 Jun
Non-invasive and non-destructive micro-XRF and micro-Raman analysis of a decorative wallpaper from the beginning of the 19th century.
2007 Feb
Interaction of omapatrilat with FD&C Blue No. 2 lake during dissolution of modified release tablets.
2007 Jul 18
Metal-mediated cyclization of aryl and benzyl glycidyl ethers: a complete scenario.
2008 Dec 17
Fabrication of FeF3 Nanoflowers on CNT branches and their application to high power lithium rechargeable batteries.
2010 Dec 7
Thermal behavior study and decomposition kinetics of amiodarone hydrochloride under isothermal conditions.
2011 Jun
Oxidative aromatic C-N bond formation: convenient synthesis of N-amino-3-nitrile-indoles via FeBr3-mediated intramolecular cyclization.
2011 May 21
Finnish wallpaper pigments in the 18th-19th century: presence of KFe3(CrO4)2(OH)6 and odd pigment mixtures.
2013 Apr
Microwave assisted convenient one-pot synthesis of coumarin derivatives via Pechmann condensation catalyzed by FeF3 under solvent-free conditions and antimicrobial activities of the products.
2014 Aug 26
FeF(3) catalyzed cascade C-C and C-N bond formation: synthesis of differentially substituted triheterocyclic benzothiazole functionalities under solvent-free condition.
2014 May
Heme Binding by Corynebacterium diphtheriae HmuT: Function and Heme Environment.
2015 Nov 3
Nazarov cyclization of 1,4-pentadien-3-ols: preparation of cyclopenta[b]indoles and spiro[indene-1,4'-quinoline]s.
2016 Feb 14
Mechanisms and origins of the switchable regioselectivity of FeBr3-catalyzed [1,2]-aryl and [1,2]-alkyl shifts of α-aryl aldehydes.
2016 Feb 28
Halide Influence on Molecular and Supramolecular Arrangements of Iron Complexes with a 3,5-Bis(2-Pyridyl)-1,2,4,6-Thiatriazine Ligand.
2016 Jun 6
Iron-Catalyzed Regioselective Transfer Hydrogenative Couplings of Unactivated Aldehydes with Simple Alkenes.
2016 May 17
Superior electrochemical performance of N-doped nanocrystalline FeF(3)/C with a single-step solid-state process.
2016 Oct 4
Ferric Chloride-induced Murine Thrombosis Models.
2016 Sep 5
Phosphorus recovery from biogas slurry by ultrasound/H(2)O(2) digestion coupled with HFO/biochar adsorption process.
2017 Feb
Effect of iron and carbon monoxide on fibrinogenase-like degradation of plasmatic coagulation by venoms of four Crotalus species.
2017 Jan
A Simplified Fe-Based PhotoATRP Using Only Monomers and Solvent.
2017 Jul
Patents

Patents

20080188032
44
20090216060
44
6258758
44
US 5206265 A
44
US2385188
44
US3873678
44
US4364871
44
US6881255
44
US6903235
44
US7198668
44
US8071067
44

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Iron oxides black, red and yellow are intended to be used as colourants in feedingstuffs for all animal species without dose or age restriction. The applicant recommends 500–1,200 mg/kg of the additives in complete (and complementary) feedingstuffs as standard dose. http://onlinelibrary.wiley.com/doi/10.2903/j.efsa.2016.4482/full
Ferric sodium citrate is an additive used in various foods such as baby milk powder, school and hospital food, beverages, cereals and supplements. It is administered orally.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Sat Dec 16 00:26:10 UTC 2023
Edited
by admin
on Sat Dec 16 00:26:10 UTC 2023
Record UNII
UBY79OCO9G
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FERRIC PYROPHOSPHATE CITRATE
USAN   WHO-DD  
USAN  
Official Name English
SOLUBLE FERRIC PYROPHOSPHATE
Common Name English
H-61
Code English
Ferric pyrophosphate citrate [WHO-DD]
Common Name English
TRIFERIC
Brand Name English
TRIFERIC AVNU
Brand Name English
FERRIC PYROPHOSPHATE CITRATE [ORANGE BOOK]
Common Name English
SFP
Common Name English
FERRIC PYROPHOSPHATE CITRATE [USAN]
Common Name English
FERRIC PYROPHOSPHATE, SOLUBLE
Common Name English
Tetraferric nonahydrogen citrate pyrophosphate
Common Name English
H61
Code English
Code System Code Type Description
DAILYMED
UBY79OCO9G
Created by admin on Sat Dec 16 00:26:10 UTC 2023 , Edited by admin on Sat Dec 16 00:26:10 UTC 2023
PRIMARY
DRUG CENTRAL
5122
Created by admin on Sat Dec 16 00:26:10 UTC 2023 , Edited by admin on Sat Dec 16 00:26:10 UTC 2023
PRIMARY
FDA UNII
UBY79OCO9G
Created by admin on Sat Dec 16 00:26:10 UTC 2023 , Edited by admin on Sat Dec 16 00:26:10 UTC 2023
PRIMARY
USAN
CD-56
Created by admin on Sat Dec 16 00:26:10 UTC 2023 , Edited by admin on Sat Dec 16 00:26:10 UTC 2023
PRIMARY
CAS
1275612-31-1
Created by admin on Sat Dec 16 00:26:10 UTC 2023 , Edited by admin on Sat Dec 16 00:26:10 UTC 2023
NO STRUCTURE GIVEN
LACTMED
Ferric Pyrophosphate Citrate
Created by admin on Sat Dec 16 00:26:10 UTC 2023 , Edited by admin on Sat Dec 16 00:26:10 UTC 2023
PRIMARY
NCI_THESAURUS
C169976
Created by admin on Sat Dec 16 00:26:10 UTC 2023 , Edited by admin on Sat Dec 16 00:26:10 UTC 2023
PRIMARY
EVMPD
SUB32445
Created by admin on Sat Dec 16 00:26:10 UTC 2023 , Edited by admin on Sat Dec 16 00:26:10 UTC 2023
PRIMARY
DRUG BANK
DB13995
Created by admin on Sat Dec 16 00:26:10 UTC 2023 , Edited by admin on Sat Dec 16 00:26:10 UTC 2023
PRIMARY
SMS_ID
300000017556
Created by admin on Sat Dec 16 00:26:10 UTC 2023 , Edited by admin on Sat Dec 16 00:26:10 UTC 2023
PRIMARY
CAS
1802359-96-1
Created by admin on Sat Dec 16 00:26:10 UTC 2023 , Edited by admin on Sat Dec 16 00:26:10 UTC 2023
PRIMARY
PUBCHEM
109374151
Created by admin on Sat Dec 16 00:26:10 UTC 2023 , Edited by admin on Sat Dec 16 00:26:10 UTC 2023
PRIMARY
RXCUI
1607975
Created by admin on Sat Dec 16 00:26:10 UTC 2023 , Edited by admin on Sat Dec 16 00:26:10 UTC 2023
PRIMARY RxNorm
ChEMBL
CHEMBL3544987
Created by admin on Sat Dec 16 00:26:10 UTC 2023 , Edited by admin on Sat Dec 16 00:26:10 UTC 2023
PRIMARY
Related Record Type Details
Structure of FERRIC CATION
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966